Loading...
•
Sep 30, 2021
Annexon Q3 2021 Earnings Report
Annexon reported financial results for the third quarter of 2021 and provided business and program highlights.
Key Takeaways
Annexon reported a net loss of $35.6 million for the third quarter of 2021. The company's cash and cash equivalents and short-term investments were $271.4 million as of September 30, 2021, which is expected to fund operating plans into 2024.
Advanced three clinical-stage product candidates in five clinical trials.
ANX005 was granted Orphan Drug designation by the FDA for the treatment of Huntington’s disease.
Conducted two C1q Series R&D Events highlighting the applicability of the company's platform.
Initial data from Phase 2 trial of ANX005 in HD is expected in the fourth quarter of 2021.
Forward Guidance
Annexon expects that its current cash position is sufficient to fund its operating plans into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...